Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.12 Insider Own86.00% Shs Outstand73.83M Perf Week-9.30%
Market Cap17.58M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.34M Perf Month-85.03%
Income-0.15M PEG- EPS next Q- Inst Own2.18% Short Float0.71% Perf Quarter-92.04%
Sales0.00M P/S- EPS this Y- Inst Trans1.77% Short Ratio0.03 Perf Half Y-91.56%
Book/sh-0.04 P/B- EPS next Y- ROA-1.04% Short Interest0.07M Perf Year-97.73%
Cash/sh0.02 P/C9.55 EPS next 5Y- ROE-2.10% 52W Range0.21 - 25.00 Perf YTD-94.77%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-99.05% Beta2.13
Dividend TTM- Quick Ratio1.59 Sales past 5Y0.00% Gross Margin- 52W Low12.84% ATR (14)0.18
Dividend Ex-Date- Current Ratio1.59 EPS Y/Y TTM-169.56% Oper. Margin0.00% RSI (14)11.82 Volatility27.02% 31.19%
Employees7 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-248.92% Payout- Rel Volume1.37 Prev Close0.26
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume2.46M Price0.24
SMA20-67.54% SMA50-87.80% SMA200-91.60% Trades Volume3,359,866 Change-8.56%
Jul-16-24 02:52PM
Jun-13-24 08:00AM
04:21PM Loading…
May-29-24 04:21PM
May-15-24 09:53AM
Mar-19-24 10:57AM
Mar-11-24 02:26PM
Jan-31-24 08:30AM
Nov-02-23 08:30AM
Oct-30-23 08:39AM
Oct-11-23 08:30AM
09:29AM Loading…
Oct-06-23 09:29AM
Sep-22-23 09:01AM
Sep-20-23 05:40PM
Sep-13-23 08:30AM
Sep-07-23 04:30PM
Aug-31-23 04:05PM
Aug-16-23 08:30AM
Conduit Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of clinical assets to address the unmet medical needs of patients, through exclusive relationships. Its medical needs in the areas of autoimmune disease and idiopathic male infertility. The company is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heilbron Jack KendrickFormer CEO,director&10% ownerSep 22 '23Option Exercise0.004,060,25004,060,250Sep 26 05:30 PM